Phase 2 N=138 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Phase 2 N=23 Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants
Phase 2 N=170 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Melanoma · Neoplasm Metastasis
Primary: Clinical Response — 0; 0; 0; 0 Participants
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 3 N=815 Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
Iris Melanoma · Medium/Large Size Posterior Uveal Melanoma · Mucosal Melanoma
Primary: Overall Survival — 69.6; 59.3 months — p=0.528
Phase 2 N=104 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Phase 2 N=24 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Acral Lentiginous Malignant Melanoma · Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size
Primary: Objective Tumor Response (Partial or Complete Response) According to RECIST — 0 participants
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=10 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Skin Cancer · Metastatic Melanoma
Primary: Response — 0; 0; 8; 2 Participants
Phase 2 N=37 Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
Melanoma
Primary: Best Objective Response Rate (BORR) — 24 percentage of patients
N/A N=34 Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Stage IA Skin Melanoma · Stage IB Skin Melanoma · Stage IIA Skin Melanoma
Primary: Level of Activated STAT1(Phospho-STAT1) — 5.96; 4.80 MU/m2 — p=.22
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 3 N=951 Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
High Risk Stage III Melanoma
Primary: Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population — 26.09; 17.05 months — p=0.0013
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 3 N=906 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Melanoma
Primary: Recurrence-free Survival (RFS) — 52.37; 24.08 Months — p=0.0003
Phase 2 N=158 Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants
Phase 2 N=20 Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Phase 2 N=34 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Uveal Melanoma
Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability
Phase 2 N=41 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate (CR + PR) — 7.5 percentage of participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=110 Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
Melanoma
Primary: Rate of Relapse-free Survival at 18 Months — 29; 28; 27; 26 Participants
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=23 Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Melanoma
Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants
Phase 2 N=24 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Phase 2 N=187 Phase IIB TL + YCWP + DC in Melanoma
Melanoma
Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Phase 2 N=20 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients